Literature DB >> 15386715

Trends in prescribing for vulvovaginal candidiasis in the United States.

Linda F McCaig1, Michael M McNeil.   

Abstract

PURPOSE: To describe trends in visits to office-based physicians in the United States by females 15-64 years of age for vulvovaginal candidiasis and related antifungal prescribing. Since January 1991, intravaginal antifungal medications have been available over-the-counter in the United States to treat vulvovaginal candidiasis.
METHODS: Data from the 1985 through 2001 National Ambulatory Medical Care Surveys (NAMCS) were examined. NAMCS is an annual national probability sample survey that collects data on the utilization of services provided by office-based physicians.
RESULTS: The average annual visit rates for symptoms of vaginitis and a diagnosis of vulvovaginal candidiasis decreased by 55 and 72%, respectively. The intravaginal antifungal prescribing rate for vulvovaginal candidiasis declined by 41%. No trend was found for total antifungal prescribing; however, during the late 1990s, fluconazole was prescribed at approximately one-third of visits with a diagnosis of vulvovaginal candidiasis.
CONCLUSION: These data suggest an increased trend in self-diagnosis and use of over-the-counter intravaginal antifungal medications. The shift from prescribing intravaginal antifungal preparations to fluconazole raises concern about the possible development of azole drug resistance. Educational efforts are needed to counter potential misuse of these medications that may contribute to increased infection with innately azole resistant non-albicans Candida species and chronic infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15386715     DOI: 10.1002/pds.960

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

Review 1.  Local treatment of vulvovaginal candidosis : general and practical considerations.

Authors:  José das Neves; Eugénia Pinto; Branca Teixeira; Gustavo Dias; Patrocínia Rocha; Teresa Cunha; Bárbara Santos; Maria H Amaral; Maria F Bahia
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  Estimation of Direct Healthcare Costs of Fungal Diseases in the United States.

Authors:  Kaitlin Benedict; Brendan R Jackson; Tom Chiller; Karlyn D Beer
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

3.  Hospital use of systemic antifungal drugs.

Authors:  Katja de With; Michaela Steib-Bauert; Holger Knoth; Frank Dörje; Egid Strehl; Ulrich Rothe; Ludwig Maier; Winfried V Kern
Journal:  BMC Clin Pharmacol       Date:  2005-02-10

4.  A question for women's health: chemicals in feminine hygiene products and personal lubricants.

Authors:  Wendee Nicole
Journal:  Environ Health Perspect       Date:  2014-03       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.